State of Alaska Department of Revenue raised its stake in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 81.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,871 shares of the specialty pharmaceutical company’s stock after buying an additional 3,081 shares during the period. State of Alaska Department of Revenue’s holdings in AMAG Pharmaceuticals were worth $126,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of the stock. Advisors Asset Management Inc. boosted its stake in AMAG Pharmaceuticals by 259.9% in the first quarter. Advisors Asset Management Inc. now owns 6,931 shares of the specialty pharmaceutical company’s stock valued at $156,000 after buying an additional 5,005 shares in the last quarter. Mason Street Advisors LLC boosted its stake in AMAG Pharmaceuticals by 7.4% in the first quarter. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock valued at $181,000 after buying an additional 554 shares in the last quarter. Sei Investments Co. boosted its stake in AMAG Pharmaceuticals by 0.7% in the first quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock valued at $188,000 after buying an additional 54 shares in the last quarter. Affinity Investment Advisors LLC boosted its stake in AMAG Pharmaceuticals by 51.4% in the first quarter. Affinity Investment Advisors LLC now owns 9,747 shares of the specialty pharmaceutical company’s stock valued at $220,000 after buying an additional 3,310 shares in the last quarter. Finally, Baird Financial Group Inc. acquired a new stake in AMAG Pharmaceuticals during the first quarter valued at $220,000.
Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) traded down 1.19% on Friday, hitting $16.55. The company had a trading volume of 413,226 shares. The company’s market capitalization is $584.02 million. AMAG Pharmaceuticals, Inc. has a 12-month low of $16.00 and a 12-month high of $36.83. The firm has a 50-day moving average price of $19.09 and a 200 day moving average price of $20.86.
AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.18. The business had revenue of $158.39 million during the quarter, compared to the consensus estimate of $158.83 million. AMAG Pharmaceuticals had a negative return on equity of 4.81% and a negative net margin of 7.58%. The firm’s quarterly revenue was up 24.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.45 EPS. Equities analysts expect that AMAG Pharmaceuticals, Inc. will post ($1.37) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This story was published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.com-unik.info/2017/08/11/state-of-alaska-department-of-revenue-boosts-position-in-amag-pharmaceuticals-inc-nasdaqamag.html.
Several equities research analysts have recently weighed in on the company. Barclays PLC reissued a “hold” rating and issued a $25.00 price objective on shares of AMAG Pharmaceuticals in a research report on Friday, May 5th. ValuEngine raised AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, July 25th. TheStreet cut AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a research report on Friday, May 5th. Citigroup Inc. reduced their price objective on AMAG Pharmaceuticals to $24.00 and set a “hold” rating for the company in a research report on Friday, July 7th. Finally, Jefferies Group LLC set a $40.00 price objective on AMAG Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, April 20th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $28.09.
In related news, SVP Julie Krop sold 4,938 shares of the business’s stock in a transaction on Thursday, July 13th. The stock was sold at an average price of $20.00, for a total value of $98,760.00. Following the completion of the sale, the senior vice president now directly owns 28,336 shares in the company, valued at approximately $566,720. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.80% of the company’s stock.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
What are top analysts saying about AMAG Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AMAG Pharmaceuticals Inc. and related companies.